Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ImmunoGen and Genentech team up

Executive Summary

Genentech licensed exclusive marketing and manufacturing rights to ImmunoGen's (cancer drugs) maytansinoid Tumor-Activated Prodrug (TAP) technology for use in anti-HER2 antibodies. Genentech will pay (uf)$2mm up front, up to $37.5mm more in up-fronts and pre-commercialization milestones, plus royalties on sales.
Deal Industry
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register